NIH makes major investments to advance human-based research infrastructure and technologies

• September 21, 2026

FDA approves combo for ESR1-mutated breast cancer

In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.

• by Kathryn Wighton

• September 21, 2026

• 2 min

Correction: Bioinformatics analysis of ferroptosis-related hub genes and immunoinfiltration in myocardial ischemia/reperfusion following heart transplantation

• by Yuxi Zhang, Qiao Tang, Jiahui Cui, Yanan Li, Heng Xu, Zhen Qiu, Shaoqing Lei, Rui Xue, Qian Sun, Zhongyuan Xia

• September 21, 2026

Geographic Variation in Low-Value Orthopedic Services Among Medicare-Enrolled Veterans

• by Sooyeon Song, Steven D. Pizer, Christine A. Yee, Samantha G. Auty

• September 21, 2026